Rebekah Jordan sits down with Oliver Schacht, CEO of OpGen, to discuss the increasing prevalence of antibiotic resistance in Urinary Tract Infections (UTIs), and how OpGen’s Unyvero can quicken the AR diagnosis process.
Key insights:
- UTIs are probably up to 10 million a year, in the US alone, the majority are found in nursing homes and long-term care facilities.
- OpGen released the Unyvero Panel to tackle the rise in AR in an underserved market - a broad panel that is simple to use, and diagnostic results are produced within five hours.
- The Unyvero Panel tests for a totality of 101 different pathogens and antimicrobial resistance markers.
- There is a need for urgency in antibiotic treatment. To tackle broad spectrum antibiotics and thus, antibiotic resistance, a more targeted and personalised approach needs to be taken.
Background
Back in 2007, Curetis started out with an idea of developing a "simple to use, throw in a sample, walk away, get an answer in a closed cartridge-based system.”